AbbVie: SKYRIZI (risankizumab) Gets EU Approval To Treat Mod

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie (ABBV) announced Wednesday that the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe active Crohn's disease.It

Related Keywords

Brussels , Bruxelles Capitale , Belgium , , European Union , European Commission , Boehringer Ingelheim , More Such Health News , Abbvie , Skyrizi , Risankizumab , Jets , Approval , Treat , Moderate , Evere , Ctive , Brohn , Disease ,